Biocon To Buttress India Market Glargine Supply From Malaysia Site

Biocon expects to meet Indian requirements for its insulin glargine with supplies from both home and abroad. It plans to import the product from its Malaysian site and will need to do Phase IV studies in Indian patients, but underscores that no price increase is likely for the imported version to ensure affordable access.